Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +441494 818 025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Director
claire@zenopa.com
+441494 818 025

Testimonials
I just wanted to say many thanks for all of you help and dedication in helping me find the job I wanted! I have found Zenopa, as a team.
Eva, 2011

Boehringer Ingelheim's NICE recommendation for Pradaxa welcomed

20 March 2012 00:00 in Pharmaceutical Company Product News


Boehringer Ingelheim's oral anticoagulant Pradaxa will provide a welcome new treatment option for stroke prevention in atrial fibrillation following its recommendation by the National Institute for Health and Clinical Excellence (NICE).

This is according to Professor Gregory Lip, consultant cardiologist and professor of cardiovascular medicine at the University of Birmingham Centre for Cardiovascular Sciences, who described NICE's decision as a "major advance" in treatment.

Final guidance issued by NICE last week backed the dabigatran etexilate therapy as a cost-effective option for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and one or more risk factors, allowing it to be widely used across the UK.

It will aid the many patients who are unable to benefit from warfarin treatment due to its side effects and need for regular monitoring.

"The approval of dabigatran etexilate has the potential to significantly reduce the risk of stroke in patients with atrial fibrillation who are eligible for anticoagulation therapy," said Professor Lip.

Pradaxa has now been approved for stroke prevention in atrial fibrillation in more than 50 countries.ADNFCR-8000103-ID-801321619-ADNFCR

Other news stories from 20/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd